In a 76‑year‑old woman with Sjögren’s syndrome who is taking daily prednisone 5 mg, can she safely receive a single dose of ketorolac (Toradol) 30 mg for pain?

A Single 30mg Dose of Ketorolac Can Be Given, But With Significant Caution in This 76-Year-Old on Daily Prednisone

While not absolutely contraindicated, administering ketorolac 30mg to this patient carries substantially elevated gastrointestinal bleeding risk due to the combination of advanced age, chronic corticosteroid use, and NSAID exposure—proceed only if the pain severity justifies this risk and no safer alternatives exist.

Risk Assessment

The FDA label for ketorolac explicitly warns that concurrent use with corticosteroids increases gastrointestinal risk 1. The 2006 consensus on NSAID use demonstrates that glucocorticoid use increases GI bleeding risk among NSAID users, with the combination of NSAIDs and corticosteroids producing relative risks exceeding 10 times baseline 2. Advanced age (76 years) independently increases risk by approximately 4% per year, and elderly patients are specifically identified as being at greater risk for serious gastrointestinal events 2.

Key Risk Factors Present:

• Age >65 years (she is 76)
• Concomitant corticosteroid use (daily prednisone 5mg)
• Ketorolac's known high GI toxicity profile compared to other NSAIDs 2

The 2013 EULAR recommendations on glucocorticoid therapy note that patients on chronic medium-dose GC treatment require consideration of comorbidities predisposing to adverse events before adding medications that increase risk 3.

Practical Decision Algorithm

If you proceed, ensure:

1. No absolute contraindications exist:

   • No active peptic ulcer disease
   • No recent GI bleeding or perforation
   • No history of peptic ulcer disease or GI bleeding
   • No advanced renal impairment (check creatinine)
   • No concurrent aspirin or other NSAID use
   • No bleeding disorders or anticoagulant use 1

2. The pain severity justifies the risk:

   • Pain should be moderate to severe (NRS ≥5)
   • Safer alternatives (acetaminophen, topical agents) have been inadequate
   • The single-dose nature limits exposure duration

3. Dosing considerations:

   • The 30mg dose is appropriate for acute pain 1
   • Recent evidence shows 10mg IV ketorolac provides equivalent analgesia to 30mg with potentially less risk 4, though oral dosing data are limited
   • Consider whether 10mg oral might suffice given her age and risk factors

4. Monitoring requirements:

   • Observe for signs of GI bleeding (melena, hematemesis, abdominal pain)
   • Monitor renal function if repeated dosing considered
   • Ensure she understands warning signs to report

Evidence on Single-Dose Safety

The 2024 meta-analysis provides some reassurance: single doses of oral ketorolac (5-30mg) compared to placebo increased risk only for trivial and mild adverse events, not serious events 5. However, this patient's concurrent prednisone use places her in a higher-risk category not fully captured by these trials.

The 2021 Cochrane review on IV ketorolac showed serious adverse events were rare overall, though elderly populations were underrepresented in trials 6. The 1990 pharmacokinetic study demonstrated that elderly patients have prolonged ketorolac half-life (7.0 hours vs 4.5 hours) and reduced clearance, suggesting they may need less frequent dosing 7.

Critical Caveats

• This is a single-dose decision only—the FDA label explicitly limits ketorolac to ≤5 days total duration 1
• Do not use ketorolac if she has taken it recently (cumulative exposure increases risk)
• The 5mg daily prednisone is relatively low-dose, which somewhat mitigates but does not eliminate the interaction risk
• Renal function must be adequate—elderly patients are at increased risk for ketorolac-induced acute renal failure 8, 9

Alternative Considerations

Before proceeding with ketorolac, consider:

• Acetaminophen (if not already maximized)
• Topical NSAIDs (if pain is localized)
• Tramadol or other non-NSAID analgesics
• Short-term opioid if pain is severe enough to warrant ketorolac

The combination of age + chronic corticosteroid + NSAID creates a multiplicative rather than additive GI bleeding risk. If the pain can be managed with safer alternatives, that is strongly preferable.